Pharmaceutical and biotech news covering drug approvals, clinical trials, FDA decisions, and pharmaceutical industry developments.
Researchers at Johns Hopkins Medicine discovered that swapping the standard mRNA modification for ac4C allows ribosomes to move twice as fast, potentially producing more therapeutic proteins. Published in Nature, this finding suggests future vaccines and treatments could be more efficient and require smaller doses.
Seeking Alpha analysts argue that President Trump's executive order altering childhood vaccine recommendations will significantly impact pharmaceutical companies. The commentary assesses how changes in recommended vaccine timing and quantity affect the financial outlook and operational strategies of major vaccine manufacturers.
Korean biotech firm EuBiologics has received World Health Organization prequalification for its typhoid conjugate vaccine. This certification allows the company to bid for international public procurement programs and resume discussions with UNICEF for immediate supply.
China relies on the United States for approximately 70% of global plasma, with over 60% of its human albumin market supplied by foreign manufacturers using US-collected blood. This heavy dependence creates significant vulnerability to potential shortages or price spikes driven by geopolitical tensions or health emergencies.
The article argues that Moderna's current stock hype regarding its cancer vaccine is disconnected from financial reality, drawing parallels to the company's pandemic-era valuation bubble. It contends that investor enthusiasm is driven by narrative extremes rather than sustainable fundamentals, suggesting a potential market correction similar to previous cycles.
IIM Ahmedabad unveiled the India Pharma Archives on Saturday, a new digital platform chronicling 125 years of the country's pharmaceutical industry. Launched by Health Minister Anupriya Patel at the IIMA Healthcare Summit, the site features thousands of documents and oral histories developed with the Indian Pharmaceutical Alliance.
Major South Korean pharmaceutical companies significantly increased research and development investments in the first half of 2026, with top firms spending over 100 billion won each. Yuhan, Chong Kun Dang, and Hanmi Pharm led these expenditures, aiming to secure future growth through new drug pipelines.
Orum Therapeutics will initiate a first-in-human Phase 1 clinical study of its investigational drug ORM-1153 by the end of 2026. The trial targets patients with relapsed or refractory acute myeloid leukemia and other hematologic malignancies, initially enrolling approximately 42 patients at U.S. sites.
Seeking Alpha analysts evaluate promising oncology companies following positive Phase 3 trial results for Moderna and Merck's mRNA-based melanoma vaccine. The commentary highlights market reactions to these clinical developments as indicators of potential investment opportunities in the sector.
The article argues that Perrigo's high dividend yield is misleading due to declining sales, shrinking margins, and recent leadership instability. It contends that despite the payout being currently covered by earnings, the company's decade-long revenue stagnation and operational weaknesses pose significant risks to income investors.